{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}],"title":"Minimal Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"Progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"ORR is defined as a Stringent Complete Response (Scr), Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) as determined by the Investigator according to International Myeloma Working Group (IMWG) Uniform Response Criteria","groups":[{"description":"Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG000","title":"Dose Escalation Cohort 1: RO7297089"},{"description":"Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG001","title":"Dose Escalation Cohort 2: RO7297089"},{"description":"Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG002","title":"Dose Escalation Cohort 3: RO7297089"},{"description":"Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG003","title":"Dose Escalation Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.","id":"OG004","title":"Dose Escalation Backfill Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.","id":"OG005","title":"Dose Escalation Cohort 5: RO7297089"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 19 months","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}